The Fierce 15: We're looking for a few excellent biotechs

 It's that time of year again.

As we prep for our ninth annual Fierce 15 report slated for the early fall, we're opening up the process for nominations. If you know a private biotech operated by some savvy execs with a promising drug development program or platform technology which deserves to be on the list, please fill out the simple survey form we've created here.

This being a topsy-turvy sort of industry filled with surprises of every kind, we've been pleased to see a number of our Fierce 15 companies go on to IPOs, buyout deals, blockbuster partnerships and big venture rounds. And we're looking for a class of 2011 which promises to follow along that trail.

There are several decisive factors in making the list. Venture backing can be crucial. So is the potential impact of their technology. If the developer has already inked a few partnerships, that would help. And the quality of the executive team, their level of experience and scientific know-how, is another telling factor.

Aside from that, we don't much care where the biotech is based. Drug development is an international game and we spread our wings wide. I'm particularly pleased that this year Executive Editor Ryan McBride will be joining me in selecting the companies and writing up the winners. In the meantime, if you'd like to suggest other special reports to me, drop me an e-mail. - John Carroll (twitter | email)

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.